Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 756-763

  Elfiky, Aymen A ^a   Cho, Daniel C ^a   McDermott, David F ^a   Rosenberg, Jonathan E ^a   Fortner, Barry ^b   Antràs, Lucia ^c   Chen, Kristina ^c   Sheng Duh, Mei ^c   Jayawant, Sujata S ^c   Oh, William K ^a   Atkins, Michael B ^a   Choueiri, Toni K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b P4 Healthcare ^*  (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Sequential therapy; Sorafenib; Sunitinib

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; PERIFOSINE; SORAFENIB; SUNITINIB; THALIDOMIDE; VASCULOTROPIN;

ADULT; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CLEAR CELL CARCINOMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81055138914     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.01.008     Document Type: Article

References (18)

1. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
2. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23:1028-1043.
3. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
4. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
7. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007, 370:2103-2111.
8. Sablin M.P., Negrier S., Ravaud A., et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009, 182:29-34.
9. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior anti-angiogenic therapy. J Urol 2008, 179:81-86.
10. Dudek A.Z., Zolnierek J., Dham A., et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115:61-67.
11. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
12. Escudier B., Choueiri T.K., Oudard S., et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: New paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007, 178:1901-1905.
13. Choueiri T.K., Rini B., Garcia J.A., et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 2007, 18:249-255.
14. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543-550.
15. Feldman D.R., Baum M.S., Ginsberg M.S., et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
16. Zimmermann K., Schmittel A., Steiner U., et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009, 76:350-354.
17. Eichelberg C., Heuer R., Chun F.K., et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: A retrospective outcome analysis. Eur Urol 2008, 54:1373-1378.
18. Rini B.I., Michaelson M.D., Rosenberg J.E., et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.